Global Head of Development Unit Established Medicines & Anti-Infectives
Dr. Hegemann oversees Novartis’ efforts in drug development to reduce the global burden of infectious and tropical diseases, including malaria. He also holds responsibility for the Established Medicines portfolio, which comprises more than 100 medicinal products, where he and his team focus on the continuous development and optimization with special emphasis on medical needs in underserved populations.
Dr. Hegemann studied at the University of Bonn (Germany) and the University of Utrecht (The Netherlands). He holds a medical doctorate and a PhD in Molecular Pharmacology. He trained as a dermatologist and has held leadership roles in drug development, spanning preclinical and clinical research, drug safety and regulatory affairs, with several pharmaceutical companies for the last two decades.